Brief Description
Supplementary Tables S1-S8. Table S1 : A set of 13 clinical/experimental drugs used in the iterative search using the MACS algorithm (pilot experiment). Table S2 : Results of generation 0 of pilot experiment. Table S3 : Results of generation 1 of pilot experiment. Table S4 : Results of generation 2 of pilot experiment. Table S5 : Results of generation 3 of pilot experiment. Table S6 : Results of generation 0 of main experiment. Table S7 : Results of generation 1 of main experiment. Table S8 
Pilot study
In a pilot study, we evaluated MACS [1] and evolved towards TACS, using an isogenic pair of human CRC cell lines DLD-1 and DLD-1KRAS/-which are isogenic except that DLD-1 expresses mutated KRAS allele whereas in DLD-1KRAS/-it is knocked out. The fitness criterion used was the survival of therapeutically more challenging DLD-1 relative to the survival of the "repaired" DLD-1KRAS/-. Thus, the optimal combination would have no effect on DLD-1KRAS/-but completely eradicate DLD-1. Drugs used in this experiment are listed in Table S1 . [13] Pilot study was initialized by generation 0 (Table S2) of MACS with 14 randomly selected combinations of arbitrary size. Largest combination consisted of 11 anti-cancer drugs while the smallest combination contained 3 drugs only. A combination J1, Rapamycin, Sunitinib and Cetuximab was found top ranked with therapeutic index 5. Generation 1 of pilot study was created as per MACS algorithm and found that top two combinations (fitness ranked 1 and 2 in Table S3 ) have therapeutic indices very similar 2.9 and 2.8, respectively. As per MACS, combination with highest therapeutic index 2.9 was selected and generation 2 was created. In generation 2 (Table  S4 ) again top ranked combination (therapeutic index 0.9) was found to have 4 other combinations ranked 2-5 with very little difference in their therapeutic indices (1, 1.2, 1.7 and 2 SI units only). These differences were within noise range of top ranked combination therefore these all were probably equal hence should be candidate for parent of new generation. By taking experimental variability into account (a step towards TACS) all these combinations were considered equal and two combinations at rank 3 and 4 with least number of drugs (4) were selected as final candidates of parent of generation 3. Among them, a combination (J1, Rapamycin, Sunitinib and Bortezomib) at rank 3 was selected due to higher rank. In generation 3 (Table S5) , search converged to a combination J1, Sunitinib and Bortezomib as the most promising. In Figure S1 , selected combinations in each generation (0-3) are assigned the different colors blue (gen 0), cyan (gen 1), yellow (gen 2), and green (gen 3), respectively. It can be noted that only one combination for each generation was used as parent of next generation. Table S2 : Results from generation 0 in pilot experiment. The columns "SI(kras) and SI(wt)" show survival indices for treatments of DLD-1KRAS/-and DLD-1 cells, respectively. The treatments used are specified in column labeled "Combinations". Column "Therapeutic Index" contains the difference (SI(kras)-SI(wt) ) between two SI values and column named "Fitness rank" specifies the rank of every combination on basis of its therapeutic index. Top ranked combination J1, Rapamycin, Sunitinib and Cetuximab was selected as parent of next generation. Table S4 : Results from generation 2 in pilot experiment. In this generation top ranked combination has therapeutic index 0.9 and it was found that differences of top ranked and other 4 combinations ranked 2-5 are very small (1, 1.2, 1.7 and 2 SI units only). These differences were within noise range of top ranked combination therefore these all combination(1-5) were probably equal hence should be candidate for parent of new generation. Column "Thr.Ind.-Std" contains difference between top ranked therapeutic index and its standard deviation, this information is helpful in determining that how many combinations are within one standard deviation of top ranked combination (therefore considered to perform the same). A column "Next Gen. candidate" indicates which combinations were selected as candidate for parent of next generation. Therefore by taking experimental variability into account (a step towards TACS) all these combinations were considered equal and two combinations at rank 3 and 4 with least number of drugs (4) were selected as final candidates of parent of generation 3. Among them combination J1, Rapamycin, Sunitinib and Bortezomib at rank 3 was selected due to higher rank. Figure S1 : Optimization overview of all iterations of pilot experiment: Here the x-axis labeled "MACS generations" shows the consecutive algorithmic iterations and y-axis shows the therapeutic indices of combinations in an iteration. Selected/best combination in each iteration was assigned a color, the iteration 0 ( random iteration) selection was assigned blue color, to track its position just follow the blue circles in different generations. Similarly, iteration 1 was assigned cyan, iteration 2 assigned yellow and iteration 3 assigned green color. Table S6 : Results from generation 0 of TACS algorithm implementation. In this generation a combination of rapamycin, 17AAG is at the top that has TI 67. Another combination of sunitinib,17AAG, Afungin is the second best combination with TI 65.5. These two combinations were perturbed around to make the generation 1. 
TACS algorithm implementation

